ZYUS Life Sciences Announces Final Approval to Commence Trading on June 19, 2023, and Engages Independent Trading Group (“ITG”) as Market Maker

ZYUS Life Sciences Corporation (the “Company”) has been approved by the TSX Venture Exchange (“TSX-V”) to commence trading on Monday, June 19, 2023, under the ticker symbol “ZYUS”.

Subject to regulatory approval, the Company has also engaged the services of Independent Trading Group ("ITG") to provide market making services in accordance with TSX-V policies. ITG will trade shares of the Company on the TSX-V and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares. Under the agreement, ITG will receive compensation of CAD$7,000 per month, payable monthly in advance. The agreement is for an initial term of three months and will renew for additional one-month terms unless terminated. The agreement may be terminated by either party with 30 days' notice. There are no performance factors contained in the agreement and ITG will not receive shares or options as compensation. ITG and the Company are unrelated and unaffiliated entities and at the time of the agreement, neither ITG nor its principals have an interest, directly or indirectly, in the securities of the Company.

About Independent Trading Group

Independent Trading Group (ITG) Inc. is a Toronto based IIROC dealer-member that specializes in market making, liquidity provision, agency execution, ultra-low latency connectivity, and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors.

About ZYUS Life Sciences

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and innovative exempt market therapeutics. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The ZYUS vision is to elevate cannabinoid-based therapeutics as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives around the world. ZYUS: Advancing the Science of Well-Being. For additional information, visit www.zyus.com.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the listing and trading of shares on the Exchange, the Company’s business, the Company’s ability to advance operations and accelerate clinical research activities, the ability of the Company to realize on its strategic plans and objectives, the ability of the Company to introduce products that act as alternatives to current pain management therapies and intentions of those subject to early warning disclosure requirements. Any such forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “contemplates”, “believes”, “projects”, “plans” and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the expected listing and trading on the Exchange, the Company’s business, the Company’s ability to advance operations and accelerate clinical research activities, the Company’s strategic plans and objectives, the Company’s ability to introduce products that act as alternatives to current pain management therapies and the intentions of those subject to early warning disclosure requirements are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Exchange will grant final approval in respect of the listing and trading of the Resulting Issuer Shares on the Exchange or that, if such listing and trading does occur, it will be completed on the terms and timing described above, that the Company will be able to advance operations and accelerate clinical research activities, that the Company will be to realize its strategic plans and objectives or that the Company will be able to introduce products that act as alternatives to current pain management therapies. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. When available, readers are encouraged to refer to the Circular for information as to the risks and other factors which may affect the Company’s business objectives and strategic plans.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230616364852/en/

ZYUS Media [e-mail] 1-833-651-7723

ZYUS Investor Relations [e-mail] 1-888-651-9987